# Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
Canonical URL: https://biopharmsignal.com/news/OCS/oculis-to-present-privosegtor-at-upcoming-clinical-trials-at-the-summit-2026
Ticker: OCS
Company: Oculis
Source: Oculis
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.oculis.com
## Summary

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an

## Article Body
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an
## Recent Company News
- 2026-07-02 08:00 EST — [Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference](https://biopharmsignal.com/news/OCS/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference-17f42704) — Source: Oculis
- 2026-07-02 08:00 EST — [Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference](https://biopharmsignal.com/news/OCS/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference-4eee9c99) — Source: Oculis
- 2026-06-25 13:46 EST — [Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026](https://biopharmsignal.com/news/OCS/oculis-to-present-privosegtor-at-upcoming-clinical-trials-at-the-summit-2026) — Source: Oculis
- 2026-06-25 13:46 EST — [Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease](https://biopharmsignal.com/news/OCS/oculis-announces-first-patient-randomized-in-predict-1-registrational-trial-of-licaminlimab-advancing-precision-medicine-in-dry-eye-disease) — Source: Oculis
- 2026-06-25 13:46 EST — [Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference](https://biopharmsignal.com/news/OCS/oculis-to-present-at-the-47th-annual-goldman-sachs-global-healthcare-conference) — Source: Oculis
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)